Sociedad Americana de Hirudoterapia

DIEP flap in breast reconstruction: A morbidity study of bilateral versus unilateral reconstruction.

Research article published in Annales de chirurgie plastique et esthetique (2023)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportEnsayos clínicosLaurent et al. · Annales de chirurgie plastique et esthetique, 2023

Abstract

BACKGROUND: The Deep Inferior Epigastric Perforator (DIEP) flap is a modality in breast reconstruction of choice. Despite its well-documented benefits and complications, a lack of evidence remains with regards to the risks of performing a bilateral versus a unilateral reconstruction. As such, we sought to compare the rates of adverse outcomes in the perioperative and postoperative periods associated with a unilateral versus a bilateral DIEP flap breast reconstruction. METHODS: A retrospective cohort study of 178 consecutive patients undergoing unilateral versus. bilateral deep inferior epigastric perforator flap breast reconstruction was performed at our tertiary care center over a 3-year period. Data on demographics, operative time, intraoperative and postoperative complications, and surgical re-exploration, were extracted for both groups. Statistical analysis was performed on a per-flap basis. RESULTS: A total of 157 unilateral and 42 bilateral deep inferior epigastric perforator flaps were identified. The rate of intra-operative complications was 12.1% for unilateral versus. 4.8% for bilateral flaps (P=0.26). Total post-operative complications rates were 30.6% for unilateral versus 54.7% for bilateral flaps (P=0.003). Surgical re-exploration was performed in 12.7% of unilateral and 11.9% of bilateral cases (P=0.88). The rate of total flap loss was similar between types of reconstruction, occurring in 2.5% of unilateral vs. 2.4% of bilateral flaps (P=1). CONCLUSION: This study demonstrates the rate of complications per flap is significantly higher in bilateral versus unilateral deep inferior epigastric perforator flap breast reconstruction. Bilateral DIEP breast reconstruction should be decided on a case-by-case basis. LEVEL OF EVIDENCE: Prognostic/Risk Study, Level II.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsHumansMastectomyRetrospective StudiesPerforator FlapMammaplastyMorbidityPostoperative ComplicationsEpigastric Arteries

Resumen

The Deep Inferior Epigastric Perforator (DIEP) flap is a modality in breast reconstruction of choice. Despite its well-documented benefits and complications, a lack of evidence remains with regards to the risks of performing a bilateral versus a unilateral reconstruction.

Por qué esto importa para la hirudoterapia

This retrospective cohort study compared perioperative and postoperative complication rates between unilateral and bilateral deep inferior epigastric perforator (DIEP) flap breast reconstructions, finding a significantly higher rate of complications per flap in bilateral procedures. The abstract outlines the risk profiles, surgical re-operation rates, and total flap loss rates associated with these complex microvascular procedures. However, the study focuses exclusively on surgical outcomes and does not detail specific salvage therapies or complications like venous congestion. The abstract contains no mention of leeches, hirudotherapy, or the leech secretome, resulting in no direct clinical relevance to the American Society of Hirudotherapy.

Citación

DIEP flap in breast reconstruction: A morbidity study of bilateral versus unilateral reconstruction.

Laurent et al. · Annales de chirurgie plastique et esthetique, 2023

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.